- €48.78bn
- €44.92bn
- $4.15bn
Brief: Argenx Announces Approval Of VYVDURA In Japan
Obesity giants will begin $80 bln M&A face-off
Obesity giants will begin $80 bln M&A face-off
Europe Research Roundup: Covivio, Mercedes-Benz Group, Persimmon
ArgenX tops BEL 20 on 'blue-sky scenario' Vyvgart progress
Brief: ArgenX: Phase 2 Data Establish Proof-Of-Concept Of Efgartigimod
European pharma stocks slip after Trump taps RFK Jr to lead top US health agency
Europe Research Roundup: Ageas SA, Argenx SE, ASMI
Argenx tops BEL 20 index after Q3 beat
Brief: Argenx Q3 Total Operating Income $589 MLN
Brief: Argenx Q3 Net Income USD 91.41 Million
Brief: Argenx's Vyvgart Shows Favorable Safety Profile From Safety Data
Argenx tops BEL 20 index, broker points to positive Vyvgart momentum
Amgen falls after reporting mixed data on two drugs
ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum
Europe Research Roundup: Argenx, Glencore, Volvo Car
Barclays ups argenx on autoimmune disease drugs potential
'Strong' Vyvgart sales boost Argenx shares
Brief: Argenx Expects Net Cash Burn Of Less Than $500 Mln In 2024